SYStemix
Beaumaris
About SYStemix
SyStemix develops cellular and cell-based gene therapies for cancer, AIDS, and genetic diseases based on the use of isolated, expanded, and gene-modified hematopoietic stem cells. The company is based in Palo Alto, California. SyStemix, Inc. was acquired by Novartis AG. In February 1997, SyStemix completed a merger with Novartis Biotech Holding Corp., an indirect wholly owned subsidiary of Novartis, Inc. Novartis shuttered Systemix in 2000.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Website: systemix.com.au
- Phone: +61 411 136 489
Social Profiles
Canonical: https://fsome.com/organization/systemix-3337355 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.